Treatment diagrams for all study patients of CoALL 07-03 treated according to the low- and high-risk arms. (A) Treatment overview for low-risk therapy in CoALL 07-03. (B) Treatment overview for high-risk therapy in CoALL 07-03. ADR, doxorubicin (30 mg/m2); C1, methotrexate (1 g/m2)/Escherichia coli–derived asparaginase (45 000 IE/m2)/6-MP (100 mg/m2 per day)/IT-MTX (age-dependent dose); C1a, methotrexate (1 g/m2)/pegylated asparaginase (2500 IE/m2)/6-MP (100 mg/m2 per day)/IT-MTX (age-dependent dose); C2, methotrexate (1 g/m2)/teniposide (VM26) (165 mg/m2)/cytarabine (300 mg/m2)/6-thioguanine (100 mg/m2 per day)/IT-MTX (age-dependent dose); C2a, methotrexate (1 g/m2)/teniposide (VM26) (165 mg/m2)/cytarabine (300 mg/m2)/6-MP (100 mg/m2 per day)/IT-MTX (age-dependent dose); C3, high-dose cytarabine (4 × 3 g/m2)/pegylated asparaginase (2500 IE/m2); C4, cyclophosphamide (900 mg/m2)/methotrexate (1 g/m2)/E coli–derived asparaginase (45 000 IE/m2)/IT-MTX (age-dependent dose); C4a, cyclophosphamide (900 mg/m2)/methotrexate (1 g/m2)/E coli–derived asparaginase (45 000 IE/m2)/6-MP (100 mg/m2 per day)/IT-MTX (age-dependent dose); Dex, dexamethasone (10 mg/m2 per day); I, induction; PEG-ASP, pegylated asparaginase (2500 IE/m2); R, randomization; R1, cyclophosphamide (900 mg/m2)/cytarabine (4 × 90 mg/m2)/6-thioguanine (100 mg/m2 per day)/IT-MTX (age-dependent dose); R1a, cyclophosphamide (900 mg/m2)/cytarabine (4 × 90 mg/m2)/6-thioguanine (100 mg/m2 per day); VCR, vincristine (1.5 mg/m2).